Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The claim accurately reflects FDA labeling for GAZYVA regarding HBV reactivation, including screening, monitoring, and discontinuation guidance, and correctly notes that the labeling includes a PML warning.
Category Scores
Accurate Statements
HBV reactivation (including a PML warning) is an adverse effect/safety risk of GAZYVA.
Label Sections 5.1 (HBV reactivation) and 5.2 (PML warning for JC virus with fatality potential).
FDA labeling provides guidance to screen, monitor, and discontinue if HBV reactivation occurs.
Section 5.1: screen with HBsAg and anti-HBc before initiating; monitor during and for several months after; and immediately discontinue GAZYVA and any concomitant chemotherapy and institute appropriate treatment if HBV reactivation develops.
Unsupported Statements
Contradictions
Important Omissions
Details that HBV reactivation can occur in HBsAg-positive, HBsAg-negative/anti-HBc-positive, and resolved infection (HBsAg-negative/anti-HBc-positive/anti-HBs-positive) patients.
Importance:
Low
The specific duration language for monitoring 'during and for several months following treatment' (timing nuance).
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
The evaluated claim is consistent with labeled safety warnings and management steps (screening/monitoring/discontinuation) and does not introduce inaccurate or conflicting safety information.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
PML is a separate warning (Section 5.2) and the claim loosely associates it with HBV reactivation; however, it remains accurate that the labeling includes a PML warning.
Suggested Improvement
Separately state that the label includes both HBV reactivation guidance (Section 5.1) and a separate PML warning with discontinuation guidance if PML develops (Section 5.2).